Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041 LOS ANGELES, Oct. 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company...
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Cancele cuando quiera · 99 CA$/mes


